West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
Zacks News
Becton Dickinson (BDX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 12.13% and 0.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
MMSI or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MMSI vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical's (WST) New Launch to Expand Portfolio
by Zacks Equity Research
West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NUMG
Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.
Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.
Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.
Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.
5 Stocks to Watch on Recent Dividend Hikes Amid Volatility
by Zacks Equity Research
Investors may keep a tab on stocks like WST, SXI, WCN, MPC and EQIX, which have lately hiked their dividend payments.
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.
Here's What Key Metrics Tell Us About West Pharmaceutical (WST) Q3 Earnings
by Zacks Equity Research
The headline numbers for West Pharmaceutical (WST) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 16.13% and 0.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Reasons to Retain West Pharmaceutical (WST) Stock for Now
by Zacks Equity Research
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
The Zacks Analyst Blog Highlights Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services
by Zacks Equity Research
Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services are part of the Zacks top Analyst Blog.
Top Research Reports for Accenture, Elevance Health & Analog Devices
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Elevance Health, Inc. (ELV) and Analog Devices, Inc. (ADI).
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from the Pharmaceutical segment's solid performance.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.